Effectiveness of low dose, low cost mifepristone in reduction of bleeding in symptomatic uterine fibroids.

Effectiveness of low dose, low cost mifepristone in management of symptomatic fibroids. - nil

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031195

Enrollment

Registered

2021-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

Intervention1: mifeprostone: 5 mg dose given daily to see reduction in bleeding for 3 months. Intervention2: nil: nil Control Intervention1: NO COMPARATOR: NO COMPARATOR

Eligibility

Inclusion criteria

Inclusion criteria: Suffering from heavy menstrual bleeding

Exclusion criteria

Exclusion criteria: Acute AUB.malignancy.other indication of surgery,type 0 submucous fibroid

Design outcomes

Primary

Measure	Time frame
Relief of bleeding .Timepoint: assessed at 1,2,3 months and then at 6 months	—

Secondary

Measure	Time frame
reduction in size of fibroidTimepoint: 3 months	—

Countries

India

Contacts

Public ContactKanika Sylonia

ABVIMS and RMLH

drrenukamalik05@gmail.com23404602

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026